Latest Paladin Labs Inc (PLDLF) Headlines
Endo International acquires Paladin Labs for USD2.7bn
M2 - Mon Mar 03, 5:21AM CST
Health care company Endo International (Endo Health Solutions) (Nasdaq:ENDP)(TSX:ENL) reported on Friday the completion of its acquisition of Paladin Labs, valued at USD2.7bn, in a stock and cash transaction.
Endo Completes Acquisition of Paladin Labs
PR Newswire Europe - Fri Feb 28, 10:15AM CST
Accretive transaction accelerates Endo's transformation into a leading specialty healthcare company -- Creates a compelling financial and operational platform for future growth -- Establishes Endo's global pharmaceuticals footprint -- Endo Health Solutions Inc. becomes Endo International plc Endo International plc , formerly Endo Health Solutions Inc., announced today that it has completed the acquisition of Paladin Labs Inc. in a stock and cash transaction currently valued at approximately $2.7 billion. The acquisition accelerates Endo's strategic transformation into a leading global specialty healthcare company and creates a platform for future growth in North America and around the globe.
Knight Therapeutics Inc. to Begin Trading on March 3, 2014
Marketwire - Fri Feb 28, 8:09AM CST
The Common Shares of Knight Therapeutics Inc. (TSX VENTURE: GUD) are now listed on the TSX Venture Exchange under the ticker symbol GUD and are expected to begin trading on March 3, 2014 at opening. Knight Therapeutics Inc. ("Knight") is owned by the former shareholders of Paladin Labs Inc. ("Paladin") pursuant to a spin-off transaction that was effected today, along with the acquisition of Paladin by Endo Health Solutions Inc. (NASDAQ: ENDP), a leading U.S.-based specialty pharmaceutical company.
Endo Health Solutions wins shareholders approval to acquire Paladin Labs
M2 - Thu Feb 27, 3:16AM CST
Healthcare company Endo Health Solutions (NasdaqGS:ENDP) revealed on Wednesday that its shareholders have approved the proposed acquisition of Paladin Labs (TSX
LB.TO).
Endo Announces Shareholder Approval of its Acquisition of Paladin Labs
PR Newswire - Wed Feb 26, 11:30AM CST
Endo Health Solutions Inc. (NASDAQ: ENDP) ("Endo") today announced that, at the shareholder meeting held today, proposals related to Endo's proposed acquisition of Paladin Labs Inc. (TSX: PLB) ("Paladin") were approved by Endo's shareholders.
Endo Announces South African Competition Act Compliance and Approval Under the Investment Canada Act in Connection with Its Proposed Acquisition of Paladin Labs
PR Newswire - Tue Feb 18, 7:30AM CST
Endo Health Solutions (Nasdaq: ENDP) today announced that the South African Competition Commission has completed its review and approved the merger of Endo and Paladin Labs without conditions in terms of section 14(1)(b) of the Competition Act (South Africa).
Competitor Analysis: Immunocytokines - 2014 Report
M2 - Mon Jan 27, 2:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/dgxmg2/competitor) has announced the addition of the "Competitor Analysis: Immunocytokines" report to their offering. The development of recombinant cytokines, or mainly antibody-cytokine fusion proteins, has been characterized by many drawbacks from dose-limiting toxicities. Over several years, development of new cytokines has stagnated, but recent R&D work with engineering of the cytokine payloads promises new molecular entities with better tolerability and safety. The present Competitive Intelligence report about Immunocytokines provides a competitor evaluation in the field of recombinant fusion proteins of a targeting moiety and a human cytokine as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of recombinant immunocytokines with first and second generation cytokine payloads. In addition, the report lists company-specific R&D pipelines of Immunocytokines. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered: - Immunocytokines with TNF as Payload - Immunocytokines with First-Generation Interleukin-2 as Payload - Immunocytokines with Second-Generation Interleukin-2 as Payload - Immunocytokines with Interleukin-10 as Payload - Immunocytokines with Interleukin-12 as Payload - Immunocytokines with Interleukin-15 as Payload - Immunocytokines with Interferon as Payload - Corporate Immunocytokine R&D Pipelines Companies Mentioned - Alkermes - Alopexx Oncology - Altor Biosciences - Apeiron Biologics - AstraZeneca - Atlab Pharma - CytImmune - Cytune Pharma - ImmunGene - Immunomedics - Merck Serono - MolMed - Nektar Therapeutics - Paladin Labs - Pfizer - Philogen (Philochem) - Roche - Targa Therapeutics - Teva Pharmacuticcals - Valor Biotherapeutics For more information visit http://www.researchandmarkets.com/research/dgxmg2/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Voinjama District Citizens Upgrading Four-Mile Road
by Korboi K. Gbelewala - All Africa Global Media - Fri Jan 17, 8:33AM CST
Citizens of Duogomai and Kortee Towns in Voinjama District, Lofa County, have started a self-help initiative to recondition a four-mile road linking the two towns.
Prisoners Facing Starvation
by Mthulisi Mathuthu - All Africa Global Media - Fri Jan 17, 8:31AM CST
About 19,000 prison inmates countrywide are facing starvation as food stocks have dropped significantly and the situation could worsen due to poor funding, parliamentarians heard Wednesday.
Focus Outlines Plans for Bayovar 12 Phosphate Project in 2014
Marketwire - Thu Jan 16, 7:31AM CST
Focus Ventures Ltd. (TSX VENTURE: FCV), the Latin American phosphate explorer, is pleased to provide an overview of the Company's 2014 plans for exploration of the Bayovar 12 phosphate project in northern Peru.
Vacation Express Expands Service to Fourth Nonstop Location in CVG
Marketwire - Tue Jan 14, 1:00PM CST
Today Vacation Express announces expanded service to Grand Bahama Island, the fourth nonstop location from the Cincinnati/Northern Kentucky International Airport (CVG). Service to Grand Bahama Island (FPO) starts on August 13, 2014 and runs through October. The flight will be operated by Bahamasair using a 737-400 that seats 150 passengers. The plane has both main and first class cabins. All passengers will get a free first checked bag, snack and open bar.
Sway Group Announces Acquisition of Massive Sway, SITS Girls, and Bloggy Boot Camp Conferences
Marketwire - Tue Jan 14, 12:11PM CST
Sway Group, a management agency for bloggers and social media influencers, is excited to announce three corporate acquisitions that have greatly expanded their audience reach and engagement. The company now owns Massive Sway, SITS Girls, and the Bloggy Boot Camp conference series, making Sway Group an unparalleled source of opportunities for brands looking to work with online publishers.
Endo Announces Early Termination of HSR Act Waiting Period and Canadian Competition Act Compliance in Connection with Its Proposed Acquisition of Paladin Labs
PR Newswire - Thu Dec 19, 9:12AM CST
Endo Health Solutions (NASDAQ: ENDP) ("Endo") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act") in connection with Endo's proposed acquisition of Paladin Labs Inc. (TSX: PLB) ("Paladin Labs") was terminated by the United States Federal Trade Commission on December 17, 2013. Endo also today announced that the Canadian Competition Bureau issued a no-action letter on December 18, 2013, which constitutes Canadian Competition Act compliance for Endo's proposed acquisition of Paladin Labs. Pursuant to the acquisition, each of Endo and Paladin Labs will be acquired by a newly-formed Irish holding company ("New Endo").
Mild Cognitive Impairment - Pipeline Review, H2 2013
M2 - Mon Nov 25, 2:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/5vvwc8/mild_cognitive) has announced the addition of the "Mild Cognitive Impairment - Pipeline Review, H2 2013" report to their offering. 'Mild Cognitive Impairment - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mild Cognitive Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mild Cognitive Impairment. Scope - A snapshot of the global therapeutic scenario for Mild Cognitive Impairment. - A review of the Mild Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mild Cognitive Impairment pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Mild Cognitive Impairment. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Mild Cognitive Impairment pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Boehringer Ingelheim GmbH Takeda Pharmaceutical Company Limited Chiesi Farmaceutici SpA Pfizer Inc. Paladin Labs Inc. Theratechnologies Inc. Suven Life Sciences Ltd. QR Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/5v..._cognitive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Paladin Labs Inc announces extension of Impavido PDUFA goal date to 19 March 2014
M2 - Tue Nov 12, 10:27AM CST
Pharmaceutical company Paladin Labs Inc (TSX LB.TO) revealed on Monday the extension of US Food and Drug Administration's (FDA) Prescription Drug User Fee Act (PDUFA) goal date for its new drug application (NDA) for Impavido (miltefosine) for the treatment of cutaneous, mucosal and visceral leishmaniasis, a parasitic disease.
Paladin Announces Extension of the Impavido(R) PDUFA Date by Three Months
Marketwire - Mon Nov 11, 3:34PM CST
Paladin Labs Inc. ("Paladin") (TSX: PLB), a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has notified Paladin that it is extending the Prescription Drug User Fee Act (PDUFA) goal date for its new drug application (NDA) for Impavido(R) (miltefosine) for the treatment of cutaneous, mucosal, and visceral leishmaniasis from December 19, 2013 to March 19, 2014.
Notice of Paladin Labs' Third Quarter 2013 Results Conference Call
Marketwire - Thu Nov 07, 3:40PM CST
Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, will release its third quarter 2013 financial results on Thursday, November 14, 2013 prior to the market opening. Following the release, Paladin will hold a conference call at 10:00 a.m. (EST) hosted by Mark Beaudet, interim President and CEO of Paladin Labs. Paladin cordially invites all interested parties to participate in this call.
Endo International acquires Paladin Labs for USD2.7bn
M2 - Mon Mar 03, 5:21AM CST
Health care company Endo International (Endo Health Solutions) (Nasdaq:ENDP)(TSX:ENL) reported on Friday the completion of its acquisition of Paladin Labs, valued at USD2.7bn, in a stock and cash transaction.
Endo Completes Acquisition of Paladin Labs
PR Newswire Europe - Fri Feb 28, 10:15AM CST
Accretive transaction accelerates Endo's transformation into a leading specialty healthcare company -- Creates a compelling financial and operational platform for future growth -- Establishes Endo's global pharmaceuticals footprint -- Endo Health Solutions Inc. becomes Endo International plc Endo International plc , formerly Endo Health Solutions Inc., announced today that it has completed the acquisition of Paladin Labs Inc. in a stock and cash transaction currently valued at approximately $2.7 billion. The acquisition accelerates Endo's strategic transformation into a leading global specialty healthcare company and creates a platform for future growth in North America and around the globe.
Knight Therapeutics Inc. to Begin Trading on March 3, 2014
Marketwire - Fri Feb 28, 8:09AM CST
The Common Shares of Knight Therapeutics Inc. (TSX VENTURE: GUD) are now listed on the TSX Venture Exchange under the ticker symbol GUD and are expected to begin trading on March 3, 2014 at opening. Knight Therapeutics Inc. ("Knight") is owned by the former shareholders of Paladin Labs Inc. ("Paladin") pursuant to a spin-off transaction that was effected today, along with the acquisition of Paladin by Endo Health Solutions Inc. (NASDAQ: ENDP), a leading U.S.-based specialty pharmaceutical company.
Endo Health Solutions wins shareholders approval to acquire Paladin Labs
M2 - Thu Feb 27, 3:16AM CST
Healthcare company Endo Health Solutions (NasdaqGS:ENDP) revealed on Wednesday that its shareholders have approved the proposed acquisition of Paladin Labs (TSX
LB.TO). Endo Announces Shareholder Approval of its Acquisition of Paladin Labs
PR Newswire - Wed Feb 26, 11:30AM CST
Endo Health Solutions Inc. (NASDAQ: ENDP) ("Endo") today announced that, at the shareholder meeting held today, proposals related to Endo's proposed acquisition of Paladin Labs Inc. (TSX: PLB) ("Paladin") were approved by Endo's shareholders.
Endo Announces South African Competition Act Compliance and Approval Under the Investment Canada Act in Connection with Its Proposed Acquisition of Paladin Labs
PR Newswire - Tue Feb 18, 7:30AM CST
Endo Health Solutions (Nasdaq: ENDP) today announced that the South African Competition Commission has completed its review and approved the merger of Endo and Paladin Labs without conditions in terms of section 14(1)(b) of the Competition Act (South Africa).
Competitor Analysis: Immunocytokines - 2014 Report
M2 - Mon Jan 27, 2:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/dgxmg2/competitor) has announced the addition of the "Competitor Analysis: Immunocytokines" report to their offering. The development of recombinant cytokines, or mainly antibody-cytokine fusion proteins, has been characterized by many drawbacks from dose-limiting toxicities. Over several years, development of new cytokines has stagnated, but recent R&D work with engineering of the cytokine payloads promises new molecular entities with better tolerability and safety. The present Competitive Intelligence report about Immunocytokines provides a competitor evaluation in the field of recombinant fusion proteins of a targeting moiety and a human cytokine as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of recombinant immunocytokines with first and second generation cytokine payloads. In addition, the report lists company-specific R&D pipelines of Immunocytokines. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered: - Immunocytokines with TNF as Payload - Immunocytokines with First-Generation Interleukin-2 as Payload - Immunocytokines with Second-Generation Interleukin-2 as Payload - Immunocytokines with Interleukin-10 as Payload - Immunocytokines with Interleukin-12 as Payload - Immunocytokines with Interleukin-15 as Payload - Immunocytokines with Interferon as Payload - Corporate Immunocytokine R&D Pipelines Companies Mentioned - Alkermes - Alopexx Oncology - Altor Biosciences - Apeiron Biologics - AstraZeneca - Atlab Pharma - CytImmune - Cytune Pharma - ImmunGene - Immunomedics - Merck Serono - MolMed - Nektar Therapeutics - Paladin Labs - Pfizer - Philogen (Philochem) - Roche - Targa Therapeutics - Teva Pharmacuticcals - Valor Biotherapeutics For more information visit http://www.researchandmarkets.com/research/dgxmg2/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Voinjama District Citizens Upgrading Four-Mile Road
by Korboi K. Gbelewala - All Africa Global Media - Fri Jan 17, 8:33AM CST
Citizens of Duogomai and Kortee Towns in Voinjama District, Lofa County, have started a self-help initiative to recondition a four-mile road linking the two towns.
Prisoners Facing Starvation
by Mthulisi Mathuthu - All Africa Global Media - Fri Jan 17, 8:31AM CST
About 19,000 prison inmates countrywide are facing starvation as food stocks have dropped significantly and the situation could worsen due to poor funding, parliamentarians heard Wednesday.
Focus Outlines Plans for Bayovar 12 Phosphate Project in 2014
Marketwire - Thu Jan 16, 7:31AM CST
Focus Ventures Ltd. (TSX VENTURE: FCV), the Latin American phosphate explorer, is pleased to provide an overview of the Company's 2014 plans for exploration of the Bayovar 12 phosphate project in northern Peru.
Vacation Express Expands Service to Fourth Nonstop Location in CVG
Marketwire - Tue Jan 14, 1:00PM CST
Today Vacation Express announces expanded service to Grand Bahama Island, the fourth nonstop location from the Cincinnati/Northern Kentucky International Airport (CVG). Service to Grand Bahama Island (FPO) starts on August 13, 2014 and runs through October. The flight will be operated by Bahamasair using a 737-400 that seats 150 passengers. The plane has both main and first class cabins. All passengers will get a free first checked bag, snack and open bar.
Sway Group Announces Acquisition of Massive Sway, SITS Girls, and Bloggy Boot Camp Conferences
Marketwire - Tue Jan 14, 12:11PM CST
Sway Group, a management agency for bloggers and social media influencers, is excited to announce three corporate acquisitions that have greatly expanded their audience reach and engagement. The company now owns Massive Sway, SITS Girls, and the Bloggy Boot Camp conference series, making Sway Group an unparalleled source of opportunities for brands looking to work with online publishers.
Endo Announces Early Termination of HSR Act Waiting Period and Canadian Competition Act Compliance in Connection with Its Proposed Acquisition of Paladin Labs
PR Newswire - Thu Dec 19, 9:12AM CST
Endo Health Solutions (NASDAQ: ENDP) ("Endo") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act") in connection with Endo's proposed acquisition of Paladin Labs Inc. (TSX: PLB) ("Paladin Labs") was terminated by the United States Federal Trade Commission on December 17, 2013. Endo also today announced that the Canadian Competition Bureau issued a no-action letter on December 18, 2013, which constitutes Canadian Competition Act compliance for Endo's proposed acquisition of Paladin Labs. Pursuant to the acquisition, each of Endo and Paladin Labs will be acquired by a newly-formed Irish holding company ("New Endo").
Mild Cognitive Impairment - Pipeline Review, H2 2013
M2 - Mon Nov 25, 2:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/5vvwc8/mild_cognitive) has announced the addition of the "Mild Cognitive Impairment - Pipeline Review, H2 2013" report to their offering. 'Mild Cognitive Impairment - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mild Cognitive Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mild Cognitive Impairment. Scope - A snapshot of the global therapeutic scenario for Mild Cognitive Impairment. - A review of the Mild Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mild Cognitive Impairment pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Mild Cognitive Impairment. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Mild Cognitive Impairment pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Boehringer Ingelheim GmbH Takeda Pharmaceutical Company Limited Chiesi Farmaceutici SpA Pfizer Inc. Paladin Labs Inc. Theratechnologies Inc. Suven Life Sciences Ltd. QR Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/5v..._cognitive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Paladin Labs Inc announces extension of Impavido PDUFA goal date to 19 March 2014
M2 - Tue Nov 12, 10:27AM CST
Pharmaceutical company Paladin Labs Inc (TSX
LB.TO) revealed on Monday the extension of US Food and Drug Administration's (FDA) Prescription Drug User Fee Act (PDUFA) goal date for its new drug application (NDA) for Impavido (miltefosine) for the treatment of cutaneous, mucosal and visceral leishmaniasis, a parasitic disease. Paladin Announces Extension of the Impavido(R) PDUFA Date by Three Months
Marketwire - Mon Nov 11, 3:34PM CST
Paladin Labs Inc. ("Paladin") (TSX: PLB), a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has notified Paladin that it is extending the Prescription Drug User Fee Act (PDUFA) goal date for its new drug application (NDA) for Impavido(R) (miltefosine) for the treatment of cutaneous, mucosal, and visceral leishmaniasis from December 19, 2013 to March 19, 2014.
Notice of Paladin Labs' Third Quarter 2013 Results Conference Call
Marketwire - Thu Nov 07, 3:40PM CST
Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, will release its third quarter 2013 financial results on Thursday, November 14, 2013 prior to the market opening. Following the release, Paladin will hold a conference call at 10:00 a.m. (EST) hosted by Mark Beaudet, interim President and CEO of Paladin Labs. Paladin cordially invites all interested parties to participate in this call.
